TY - JOUR
T1 - Lynch syndrome and Muir-Torre phenotype associated with a recurrent variant in the 3’UTR of the MSH6 gene
AU - Cini, Giulia
AU - Carnevali, Ileana
AU - Sahnane, Nora
AU - Chiaravalli, Anna Maria
AU - Dell'Elice, Anastasia
AU - Maestro, Roberta
AU - Pin, Elisa
AU - Bestetti, Ilaria
AU - Radovic, Slobodanka
AU - Armelao, Franco
AU - Viel, Alessandra
AU - Tibiletti, Maria Grazia
N1 - Funding Information:
We are grateful to Dr. Giancarlo Marra for his suggestions and comments to improve this study. Research supported by Italian Ministry of Health, Ricerca Corrente of CRO Aviano, Line 1, Project “Genetics of hereditary/familial tumors” and Associazione Federica per la Vita.
Publisher Copyright:
© 2021 Elsevier Inc.
PY - 2021/6
Y1 - 2021/6
N2 - A MSH6 3’UTR variant (c.*23_26dup) was found in 13 unrelated families consulted for Lynch/Muir-Torre Syndrome. This variant, which is very rare in the genomic databases, was absent in healthy controls and strongly segregated with the disease in the studied pedigrees. All tumors were defective for MSH2/MSH6/MSH3 proteins expression, but only MSH2 somatic pathogenic mutations were found in 5 of the 12 sequenced tumors. Moreover, we had no evidence of MSH6 transcript decrease in carriers, whereas MSH2 transcript was downregulated. Additional evaluations performed in representative carriers, including karyotype, arrayCGH and Linked-Reads whole genome sequencing, failed to evidence any MSH2 germline pathogenic variant. Posterior probability of pathogenicity for MSH6 c.*23_26dup was obtained from a multifactorial analysis incorporating segregation and phenotypic data and resulted >0.999, allowing to classify the variant as pathogenic (InSiGHT Class 5). Carriers shared a common haplotype involving MSH2/MSH6 loci, then a cryptic disease-associated variant, linked with MSH6 c.*23_26dup, cannot be completely excluded. Even if it is not clear whether the MSH6 variant is pathogenic per se or simply a marker of a disease-associated MSH2/MSH6 haplotype, all data collected on patients and pedigrees prompted us to manage the variant as pathogenic and to offer predictive testing within these families.
AB - A MSH6 3’UTR variant (c.*23_26dup) was found in 13 unrelated families consulted for Lynch/Muir-Torre Syndrome. This variant, which is very rare in the genomic databases, was absent in healthy controls and strongly segregated with the disease in the studied pedigrees. All tumors were defective for MSH2/MSH6/MSH3 proteins expression, but only MSH2 somatic pathogenic mutations were found in 5 of the 12 sequenced tumors. Moreover, we had no evidence of MSH6 transcript decrease in carriers, whereas MSH2 transcript was downregulated. Additional evaluations performed in representative carriers, including karyotype, arrayCGH and Linked-Reads whole genome sequencing, failed to evidence any MSH2 germline pathogenic variant. Posterior probability of pathogenicity for MSH6 c.*23_26dup was obtained from a multifactorial analysis incorporating segregation and phenotypic data and resulted >0.999, allowing to classify the variant as pathogenic (InSiGHT Class 5). Carriers shared a common haplotype involving MSH2/MSH6 loci, then a cryptic disease-associated variant, linked with MSH6 c.*23_26dup, cannot be completely excluded. Even if it is not clear whether the MSH6 variant is pathogenic per se or simply a marker of a disease-associated MSH2/MSH6 haplotype, all data collected on patients and pedigrees prompted us to manage the variant as pathogenic and to offer predictive testing within these families.
KW - Lynch syndrome
KW - MSH2
KW - MSH6
KW - Muir-Torre syndrome
KW - Predictive testing
UR - http://www.scopus.com/inward/record.url?scp=85100436656&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85100436656&partnerID=8YFLogxK
U2 - 10.1016/j.cancergen.2021.01.005
DO - 10.1016/j.cancergen.2021.01.005
M3 - Article
C2 - 33516942
AN - SCOPUS:85100436656
SN - 2210-7762
VL - 254-255
SP - 1
EP - 10
JO - Cancer genetics
JF - Cancer genetics
ER -